PROCEPT Lawsuit, Widening Losses Cloud Q2 Earnings

Forward-Looking Analysis

PROCEPT BioRobotics (PRCT) is scheduled to report its second-quarter 2026 earnings on August 4, 2026. Consensus analyst forecasts indicate a significant deterioration in profitability, with the EPS estimate set at -$0.46, a decline from the -$0.35 reported in the same quarter of the previous year. This negative variance suggests continued pressure on margins despite revenue growth. Revenue expectations for Q2 2026 are estimated at $94.8 million, reflecting a robust year-over-year increase from the $79.18 million recorded in Q2 2025 and an upward trajectory from the $83.13 million achieved in Q1 2026. The consensus revenue estimate aligns closely with the company's provided guidance range of $91.0 million to $95.0 million. Analyst sentiment remains cautiously optimistic on growth potential, with a "Moderate Buy" rating based on nine analysts. However, the widening net loss, projected to exceed the -$31.64 million net income from Q1 2026, highlights ongoing operational challenges. The trailing twelve-month EPS stands at -$1.82, with long-term forecasts suggesting earnings per share will improve to -$0.84 over the next year, indicating a gradual path toward profitability amidst current losses.

Historical Performance Review

In the first quarter of 2026, PROCEPT BioRobotics reported total revenue of $83.13 million, marking a 20.1% year-over-year increase and surpassing the consensus estimate of $80.52 million. Despite top-line growth, the company posted a net income of -$31.64 million, representing a 6.01% decrease from the previous quarter. The earnings per share (EPS) came in at -$0.56, missing the consensus estimate of -$0.55 by one cent and reflecting a 24.44% decline compared to the prior year's quarter. Gross profit was recorded at $53.95 million during this period. These results underscore the company's ability to drive revenue growth while facing persistent margin compression and widening net losses, a trend that investors will scrutinize closely ahead of the Q2 report.

Additional News

PROCEPT BioRobotics faces a securities class action lawsuit alleging violations of federal securities laws regarding the disclosure of sales practices. The lawsuit, with a lead plaintiff deadline of September 22, 2026, claims the company withheld information about an undisclosed bulk order discount program that incentivized customers to place excessive orders, pulling forward sales and inflating reported unit sales. Allegations state that this practice led to excess customer inventory of over 10,000 handpiece units and a subsequent 30% sequential crater in U.S. handpiece sales. The complaint cites multiple earnings reports from August 2025 through February 2026, where handpiece sales missed estimates and management admitted to not properly managing customer inventory. The stock price declined over 48% from August 2025 to February 2026 following these disclosures. Multiple law firms, including Hagens Berman, Kessler Topaz, and Robbins Geller, are encouraging investors with losses to participate in the class action, citing undisclosed inventory issues and sales pull-in concerns as the basis for the legal claims.

Summary & Outlook

PROCEPT BioRobotics demonstrates strong revenue growth but suffers from deteriorating profitability, with Q1 2026 EPS missing estimates and net losses widening. The primary risk factor is the securities class action lawsuit alleging undisclosed discount programs and inventory manipulation, which has significantly impacted investor confidence and stock price. While long-term forecasts suggest a gradual improvement in EPS, the immediate outlook is clouded by legal liabilities and margin pressures. The stock's trading near the bottom of its 52-week range reflects this uncertainty. Given the legal overhang and widening losses, the near-term prospects appear bearish, requiring clear evidence of improved inventory management and sales transparency to restore market trust and reverse the negative earnings trend.